Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines

European Journal of Gynaecological Oncology

Volumn 25, Issue 1, 2004, Pages 55-60

  Kamata, Y ^a   Watanabe, J ^a   Hata, H ^b   Hamano, M ^a   Kuramoto, H ^a  

^a KITASATO UNIVERSITY   (Japan)

^b Tokyo P and Telecom Hospital   (Japan)

Author keywords

Endometrial carcinoma; HEC 1 A; Immunoblotting; Immunocytochemistry; Ishikawa; Mutation; p53

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; LABELING INDEX; POINT MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DNA PRIMERS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0842328485     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Miller C., Mohandas T., Wolf D., Prokocimer M., Rotter V., Koeffler H. P.: "Human p53 gene localized to short arm of chromosome 17". Nature, 1986, 319, 783.
2. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C.: "Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis". Cancer Res., 1994, 54, 4855.
3. Ashcroft M., Vousden K.H.: "Regulation of p53 stability". Oncogene, 1999, 18, 7637.
4. Kubbutat M. H. G., Vousden K. H.: "Keeping an old friend under control: Regulation of p53 stability". Mol. Med. Today, 1998, 4, 250.
5. Athanassiadou P., Petrakakou E., Liossi A., Nakopoulou L., Zerva C., Dimopoulos A., Athanassiades P.: "Prognostic Significance of p53, bcl-2, and EGFR in Carcinoma of the Endometrium". Acta cytol., 1999, 43, 1039.
6. Reinartz J.J., George E., Lindgren B.R., Niehans G.A.: "Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and correlation with survival and known predictors of survival". Human Pathol., 1994, 25, 1075.
7. Enomoto T., Fujita M., Inoue M., Rice J. M., Nakajima R., Tanizawa O., Nomura T.: "Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterin endometrium". Cancer Res., 1993, 53, 1883.
8. Kohler M. F., Berchuck A., Davidoff A. M., Humphrey P. A., Dodge R. K., Iglehart J. D. et al.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Res., 1992, 52, 1622.
9. Salvesen H.B., Iversen O.E., Akslen L.A.: "Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study". J. Clin. Oncol., 1999, 17, 1382.
10. Lax S.F., Kendall B., Tashiro H., Slebos R. J. C., Ellenson L. H.: "The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma evidence of distinct molecular genetic pathways". Cancer, 2000, 88, 814.
11. Ito K., Sasano H., Matunaga G., Sato S., Yajima A., Nasim S., Garret C. T.: "Correlations between p21 expression and clinicopathological findings, p53 gene and patients with endometrial carcinoma". J. Pathol., 1997, 183, 318.
12. Niwa K., Murase T., Morishita S., Hashimoto M., Itoh N., Tamaya T.: "p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status". Cancer Detec. Prev., 1999, 23, 147.
13. Stewart R. L., Royds J. A., Burton J.L., Heatley M. K., Wells M.: "Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein". Histopathology, 1998, 33, 440.
14. Kuramoto H., Nishida M., Morisawa T., Hamano M., Hata H., Kato Y. et al.: "Establishment and characterization of human endometrial cancer cell lines". Annals N. Y. Acad. Sci., 1991, 622, 402.
15. Uchida T., Wada C., Shitara T., Egawa S., Koshiba, K.: "Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer". Br. J. Cancer, 1993, 68, 751.
16. Bodner S. M., Minna J. D., Jensen S. M., D'Amico D., Carbone D., Mitsudomi T. et al.: "Expression of mutant p53 protein in lung cancer correlates with the class of p53 gene mutation". Oncogene, 1992, 7, 746.
17. Shahin M. S., Hughes J. H., Sood A. K., Buller R. E.: "The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma". Cancer, 2000, 89, 2006.